Q-omics provides the consensus-scored SH3TC2-DT profile across patient tissues and cancer cell-line models. SH3TC2-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SH3TC2-DT is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, SH3TC2-DT RNA expression shows 13,143 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where SH3TC2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3TC2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3TC2-DT survival associations across molecular data types. SH3TC2-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3TC2-DT RNA expression–survival associations across cancer types. High SH3TC2-DT expression shows unfavorable associations in ACC, KIRC, PAAD, KICH and UVM, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for SH3TC2-DT RNA expression.
This table summarizes SH3TC2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SH3TC2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3TC2-DT shows lower tumor expression in UCEC and BRCA and higher tumor expression in BLCA, COAD, HNSC and KIRP. The BLCA box plot shows higher SH3TC2-DT RNA expression in tumor versus normal tissue (log2 FC = +0.390, t-test p < 0.001).
This table shows molecular features associated with SH3TC2-DT in patient tissues and cancer cell lines. In patient samples, SH3TC2-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
